# Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

> **NCT01402089** · PHASE4 · COMPLETED · sponsor: **Markus Joerger** · enrollment: 54 (actual)

## Conditions studied

- Non Small-cell Lung Cancer
- Renal-cell Cancer
- Gastrointestinal Stroma Tumor

## Interventions

- **DRUG:** Sunitinib
- **DRUG:** Erlotinib
- **DRUG:** Midazolam
- **DRUG:** Caffeine

## Key facts

- **NCT ID:** NCT01402089
- **Lead sponsor:** Markus Joerger
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2015-07
- **Final completion:** 2015-11
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2016-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01402089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01402089, "Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01402089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*